Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Michael R. Megna Sells 9,051 Shares of Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Michael R. Megna sold 9,051 shares of the business’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total value of $203,194.95. Following the completion of the sale, the chief accounting officer now directly owns 26,528 shares in the company, valued at $595,553.60. This represents a 25.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Kiniksa Pharmaceuticals Trading Up 2.0 %

Shares of KNSA stock opened at $22.61 on Friday. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $16.56 and a 1-year high of $28.15. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of -161.49 and a beta of 0.48. The stock’s fifty day simple moving average is $19.95 and its 200-day simple moving average is $22.22.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $122.50 million for the quarter, compared to analysts’ expectations of $123.42 million. During the same quarter in the prior year, the firm posted $0.35 EPS. The business’s quarterly revenue was up 46.9% compared to the same quarter last year. On average, sell-side analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP purchased a new position in Kiniksa Pharmaceuticals in the third quarter valued at about $1,192,000. JPMorgan Chase & Co. purchased a new position in Kiniksa Pharmaceuticals in the third quarter valued at about $4,997,000. Parkman Healthcare Partners LLC lifted its position in shares of Kiniksa Pharmaceuticals by 16.7% in the third quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock worth $18,874,000 after buying an additional 108,102 shares during the last quarter. Segall Bryant & Hamill LLC acquired a new stake in shares of Kiniksa Pharmaceuticals in the third quarter worth about $675,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter worth about $355,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on KNSA shares. Citigroup initiated coverage on Kiniksa Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $40.00 price objective on the stock. Wedbush restated an “outperform” rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $37.17.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.